News & Insights
News, partnership updates and platform insights.
Follow Foreseen’s news, updates and partnerships.
Abstract CT087: Phase I/II FIH study of IPN60300, a first-in-class ADC targeting ITGA2, to assess the safety, tolerability, PK, biomarkers, immunogenicity and antitumor activity in adults with locally advanced solid tumors
AACR published a clinical-trial abstract describing the ongoing Phase I/II first-in-human study of IPN60300, a first-in-class ADC targeting ITGA2, in adults with locally advanced solid tumors.
Source: aacrjournals.orgAbstract 1665: Preclinical characterization of IPN60300, a first-in-class ITGA2 antibody-drug conjugate for cancer therapy
AACR published a preclinical characterization abstract for IPN60300, an ITGA2-targeting antibody-drug conjugate for cancer therapy.
Source: aacrjournals.orgAbstract 4444: Integrin alpha-2 (ITGA2) is a novel and well-suited antibody-drug conjugate (ADC) target
AACR published an abstract describing ITGA2 as a novel and well-suited antibody-drug conjugate target and referencing IPN60300 in the ITGA2-targeted ADC context.
Source: aacrjournals.orgAbstract 7686: Identification of a first-in-class therapeutic target using machine learning enabled translational-optimized proteomics system (TPS)
AACR published an abstract describing TPS-enabled target identification and referencing FS001 / IPN60300.
Source: aacrjournals.orgIpsen and Foreseen Biotechnology announce exclusive global licensing agreement for FS001
Foreseen granted Ipsen global development, manufacturing and commercialization rights for FS001, an ADC candidate with first-in-class potential.
Source: ipsen.comBuilding an upstream engine for novel target discovery
Foreseen’s platform strategy focuses on discovering highly differentiated targets at the source of drug and diagnostic innovation.
From clinical proteomics to translatable therapeutic targets
Integrated proteomics and AI analytics can help connect disease biology, biomarker discovery and therapeutic target validation.